Scholarlink

<p>In the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF) in addition to the “fantastic four”, a&#xa0;potential fifth pillar is emerging with low-dose digitoxin, while finerenone broadens the spectrum of mineralocorticoid receptor antagonists, particularly in HF with mildly reduced EF (HFmrEF)/HF with preserved EF (HFpEF). For HFpEF sodium-glucose linked transporter&#xa0;2 (SGLT2) inhibitors and glucagon-like peptide&#xa0;1 (GLP-1) receptor agonists are coming to the foreground through gains in morbidity and quality of life. Further innovations include myosin inhibitors in hypertrophic cardiomyopathy, de-escalated dual antiplatelet therapy (DAPT) regimens after acute coronary syndrome (ACS) and factor&#xa0;XI inhibitors as a&#xa0;potentially safer option regarding the risk of bleeding. In prevention, proprotein convertase subtilisin/kexin type&#xa0;9 (PCSK9) inhibition including small interfering RNA (siRNA)-based approaches targeting lipoprotein (a) as well as RNA-based and aldosterone synthase-based hypertension therapy and microRNA targeting mark the path towards individualized cardiovascular precision medicine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Kardiovaskuläre Pharmakotherapie im Zeitalter RNA-basierter Präzisionsmedizin

  • 期刊论文

  • 发表日期：

    2026年4月7日

查看全文
  • Anselm A. Derda,
  • Anna Hohneck

摘要

In the pharmacotherapy of heart failure with reduced ejection fraction (HFrEF) in addition to the “fantastic four”, a potential fifth pillar is emerging with low-dose digitoxin, while finerenone broadens the spectrum of mineralocorticoid receptor antagonists, particularly in HF with mildly reduced EF (HFmrEF)/HF with preserved EF (HFpEF). For HFpEF sodium-glucose linked transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists are coming to the foreground through gains in morbidity and quality of life. Further innovations include myosin inhibitors in hypertrophic cardiomyopathy, de-escalated dual antiplatelet therapy (DAPT) regimens after acute coronary syndrome (ACS) and factor XI inhibitors as a potentially safer option regarding the risk of bleeding. In prevention, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition including small interfering RNA (siRNA)-based approaches targeting lipoprotein (a) as well as RNA-based and aldosterone synthase-based hypertension therapy and microRNA targeting mark the path towards individualized cardiovascular precision medicine.